Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Director | May 02, 2024 | May 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 02, 2024 · Filed May 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,485.82 |
Ending reported balance
After 2024-05-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-05-02 · Exercise / conversion · Acquired 29,350 · Balance 33,835.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. Row 2 · 2024-05-02 · Sale · Disposed 12,207 · Balance 21,628.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F2: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2024-05-02 · Sale · Disposed 17,143 · Balance 4,485.82 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023. F3: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $36.75 · Expires 2024-05-10 | Direct | 0 |
Reported balance
After 2024-05-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-02 · Exercise / conversion · Disposed 29,350 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectBy Living Trust | 4,038,377 |
Reported balance
Holding disclosure · report date 2024-05-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 4,038,377 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023.
F2: This transaction was executed in multiple trades at prices ranging from $84.865 to $85.420. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $83.860 to $84.860. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2021 Filed Oct 2, 2021 01:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 14,132 | $112.17 | $1,585,186.44 |
DisclosureSEC source: 0001225208-21-012665 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,119.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $111.6600 to $112.6200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2021 Filed Oct 2, 2021 01:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-012665 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,251.82 Read SEC document |
| October 01, 2021 Filed Oct 2, 2021 01:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 300 | $113.10 | $33,930.00 |
DisclosureSEC source: 0001225208-21-012665 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,751.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $112.9700 to $113.3250. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 01, 2021 Filed Oct 2, 2021 01:06 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 45,050 | $21.76 | $980,288.00 |
DisclosureSEC source: 0001225208-21-012665 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,051.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 20:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 45,050 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-21-012422 · doc4.xml · derivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,400 Underlying: Common Stock · 45,050 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 20:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-012422 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,197,787 Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 20:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 27,567 | $121.29 | $3,343,601.43 |
DisclosureSEC source: 0001225208-21-012422 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,001.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $120.9400 to $121.8700. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 20:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-012422 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,568.82 Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 20:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,983 | $120.53 | $600,600.99 |
DisclosureSEC source: 0001225208-21-012422 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,068.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $119.9300 to $120.9300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 20:07 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 45,050 | $21.76 | $980,288.00 |
DisclosureSEC source: 0001225208-21-012422 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,051.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. Read SEC document |
| August 03, 2021 Filed Aug 3, 2021 23:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 45,050 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-21-011090 · doc4.xml · derivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,450 Underlying: Common Stock · 45,050 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2021 Filed Aug 3, 2021 23:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-011090 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,185,287 Read SEC document |
| August 03, 2021 Filed Aug 3, 2021 23:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 18,293 | $114.41 | $2,092,902.13 |
DisclosureSEC source: 0001225208-21-011090 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,001.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $114.1500 to $114.7100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 03, 2021 Filed Aug 3, 2021 23:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 14,257 | $113.80 | $1,622,446.60 |
DisclosureSEC source: 0001225208-21-011090 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,294.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $113.1450 to $114.1400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 03, 2021 Filed Aug 3, 2021 23:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-011090 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,551.82 Read SEC document |
| August 03, 2021 Filed Aug 3, 2021 23:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 45,050 | $21.76 | $980,288.00 |
DisclosureSEC source: 0001225208-21-011090 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,051.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. Read SEC document |
| August 03, 2021 Filed Jan 29, 2022 00:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 108,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-001132 · doc5.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,294,017 F1 · balance_after: Reflects the amount owned following this transaction as of August 3, 2021. The total amount owned as of December 31, 2021, which is the Issuer's fiscal year end, is 3,344,017 shares. Read SEC document |
| August 03, 2021 Filed Jan 29, 2022 00:09 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 108,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-001132 · doc5.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,271.82 Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 00:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 45,050 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-21-009995 · doc4.xml · derivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,500 Underlying: Common Stock · 45,050 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 00:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-009995 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,172,787 Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 00:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 16,382 | $104.78 | $1,716,505.96 |
DisclosureSEC source: 0001225208-21-009995 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,001.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $104.6850 to $104.9700. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 00:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 16,168 | $104.43 | $1,688,424.24 |
DisclosureSEC source: 0001225208-21-009995 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,383.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $103.6800 to $104.6800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 00:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-009995 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,551.82 Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 00:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 45,050 | $21.76 | $980,288.00 |
DisclosureSEC source: 0001225208-21-009995 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,051.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 00:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 45,050 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-21-009152 · doc4.xml · derivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,550 Underlying: Common Stock · 45,050 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 00:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-009152 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,160,287 Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 00:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 32,550 | $97.23 | $3,164,836.50 |
DisclosureSEC source: 0001225208-21-009152 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,001.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $96.8350 to $97.7900. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 00:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-009152 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,551.82 Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 00:05 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 45,050 | $21.76 | $980,288.00 |
DisclosureSEC source: 0001225208-21-009152 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,051.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2021. Read SEC document |
| May 24, 2021 Filed May 25, 2021 23:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 33,000 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-21-008559 · doc4.xml · derivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,600 Underlying: Common Stock · 33,000 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 24, 2021 Filed May 25, 2021 23:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 26,377 | $95.55 | $2,520,322.35 |
DisclosureSEC source: 0001225208-21-008559 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,001.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 3, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $94.9200 to $95.9200. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 24, 2021 Filed May 25, 2021 23:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,623 | $96.13 | $636,668.99 |
DisclosureSEC source: 0001225208-21-008559 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,378.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 3, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $95.9400 to $96.4250. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 24, 2021 Filed May 25, 2021 23:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 33,000 | $21.76 | $718,080.00 |
DisclosureSEC source: 0001225208-21-008559 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,001.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 3, 2020. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 69,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-008299 · doc4.xml · derivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 69,562 shares Expires 2025-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 69,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-008299 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,001.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 05, 2021 Filed May 6, 2021 01:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 65,550 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-21-007651 · doc4.xml · derivative · entry 9 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,550 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2021 Filed May 6, 2021 01:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 7 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,147,787 Read SEC document |
| May 05, 2021 Filed May 6, 2021 01:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 33,450 | $92.23 | $3,085,093.50 |
DisclosureSEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,014.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 3, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $91.7250 to $92.7000. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2021 Filed May 6, 2021 01:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,464.82 Read SEC document |
| May 05, 2021 Filed May 6, 2021 01:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 2,100 | $93.00 | $195,300.00 |
DisclosureSEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,464.82 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 3, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $92.7400 to $93.5600. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2021 Filed May 6, 2021 01:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 65,550 | $13.98 | $916,389.00 |
DisclosureSEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,564.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 3, 2020. Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 26,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007709 · doc4.xml · derivative · entry 5 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,800 Underlying: Common Stock · 26,800 shares Expires 2028-05-03 F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 210,000 | $0.00 Strike: $93.31 | $0.00 |
DisclosureSEC source: 0001225208-21-007709 · doc4.xml · derivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2028-05-03 F3 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:11 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 21,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007709 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,439.82 F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| April 27, 2021 Filed May 6, 2021 01:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 114,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,117,787 Read SEC document |
| April 27, 2021 Filed May 6, 2021 01:40 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 114,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007651 · doc4.xml · nonDerivative · entry 1 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,014.82 Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 00:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 98,550 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001225208-21-006691 · doc4.xml · derivative · entry 6 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,550 Underlying: Common Stock · 98,550 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 00:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-006691 · doc4.xml · nonDerivative · entry 4 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Living Trust Disclosed balance after: 3,003,582 Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 00:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 68,550 | $84.45 | $5,789,047.50 |
DisclosureSEC source: 0001225208-21-006691 · doc4.xml · nonDerivative · entry 3 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,220.46 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 3, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $84.0500 to $85.0300. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 08, 2021 Filed Apr 9, 2021 00:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-006691 · doc4.xml · nonDerivative · entry 2 MUSSALLEM MICHAEL A · CIK 0001204551 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,770.46 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.